You are here: Industry Insights > Herceptin

News List

Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
UK cancer centre to offer breast cancer treatment at home pharmatimes
April 29, 2021
The Christie NHS Foundation Trust has become the first cancer centre in the UK to offer the treatment Phesgo, developed by Roche’s Genentech division, for breast cancer at home.
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar prnasia
March 25, 2021
In a press conference today, EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint.
Accord Healthcare launches Herceptin biosimilar in the UK pharmatimes
September 27, 2020
Accord Healthcare has launched Zercepac (trastuzumab), a biosimilar of Roche’s Herceptin, in the UK after winning approval from the European Commission in July.
Merck announces US launch of ONTRUZANT, a biosimilar of Herceptin pharmaceutical-business-review
April 20, 2020
Merck announced the US launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin.
Halozyme Announces FDA Accepted BLA for Fixed-Dose Subcutaneous Perjeta, Herceptin Combination americanpharmaceuticalreview
March 05, 2020
Halozyme Therapeutics announced the U.S. Food and Drug Administration has accepted a Biologics License Application (BLA) from Genentech ...
Mylan, Biocon Launch Trastuzumab Biosimilar, Ogivri in the U.S. americanpharmaceuticalreview
December 30, 2019
Mylan and Biocon announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab).
Data shows non-inferiority of SC administration of Roche’s Perjeta and Herceptin pharmaceutical-technology
December 16, 2019
Roche has published data demonstrating non-inferiority of a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) administered through ...
Herceptin drops on contracting ahead of U.S. biosim, but Roche sales stomp anyway July 28, 2019
Biosimilars to Roche’s top-selling cancer drugs Herceptin and Avastin entered the U.S. last week. But thanks to PD-L1 inhibitor Tecentriq, hemophilia drug Hemlibra and multiple sclerosis therapy Ocrevus, Roche is still counting on sales growth this year.
Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue® (Trastuzumab Biosimilar) b3cnewswire
June 24, 2019
Prestige BioPharma announced positive top-line results from a Phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics (PK) of biosimilar candidate HD201 to Herceptin (trastuzumab).

Previous page 1 2 3 Next page